118 related articles for article (PubMed ID: 31203267)
1. Low-serum testosterone and high-chromogranin A rare case associated with high-grade prostate cancer and higher pathological stages of the disease.
Izzo L; Cardi A; Pugliese F; Izzo S; Izzo P; Valabrega S; Messineo D; Pieretti G
Ann Ital Chir; 2019; 90():451-456. PubMed ID: 31203267
[TBL] [Abstract][Full Text] [Related]
2. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
3. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
5. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
7. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
8. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Custovic Z; Kraus O; Tomaskovic I; Tarle M
Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort.
De Nunzio C; Albisinni S; Presicce F; Lombardo R; Cancrini F; Tubaro A
Urol Oncol; 2014 Feb; 32(2):80-4. PubMed ID: 23153859
[TBL] [Abstract][Full Text] [Related]
10. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
11. Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma.
Sciarra A; Gentile V; Monti S; Mariotti G; Pastore A; Di Silverio F
Arch Androl; 2003; 49(1):39-48. PubMed ID: 12647777
[TBL] [Abstract][Full Text] [Related]
12. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
[TBL] [Abstract][Full Text] [Related]
13. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
15. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.
Jentzmik F; Schnoeller TJ; Cronauer MV; Steinestel J; Steffens S; Zengerling F; Al Ghazal A; Schrader MG; Steinestel K; Schrader AJ
Int J Urol; 2014 Oct; 21(10):980-6. PubMed ID: 24865433
[TBL] [Abstract][Full Text] [Related]
16. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
[TBL] [Abstract][Full Text] [Related]
17. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
Appetecchia M; Meçule A; Pasimeni G; Iannucci CV; De Carli P; Baldelli R; Barnabei A; Cigliana G; Sperduti I; Gallucci M
J Exp Clin Cancer Res; 2010 Dec; 29(1):166. PubMed ID: 21162758
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
19. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
[TBL] [Abstract][Full Text] [Related]
20. Implications of circulating chromogranin A in prostate cancer.
Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]